{
  "generated": "2025-11-06T07:17:28.309527+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/immune/resveratrol-infl-inf08/inflammation/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "INFL-INF08_01",
      "year": 2016,
      "design": "randomized controlled trial",
      "journal": "inflammation_journal",
      "outcome": "recovery",
      "population": "Adults with recovery concerns",
      "adverse_events": "Transient headache",
      "doi": "10.1234/resveratrol-infl-inf08-01",
      "url": "https://doi.org/10.1234/resveratrol-infl-inf08-01",
      "citation": "INFL-INF08_01 (2016); Journal: inflammation_journal; Design: randomized controlled trial; Population: Adults with recovery concerns; Outcome: recovery; DOI: 10.1234/resveratrol-infl-inf08-01; Adverse Events: Transient headache."
    },
    {
      "study_id": "INFL-INF08_02",
      "year": 2017,
      "design": "randomized controlled trial",
      "journal": "inflammation_journal",
      "outcome": "recovery",
      "population": "Adults with recovery concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/resveratrol-infl-inf08-02",
      "url": "https://doi.org/10.1234/resveratrol-infl-inf08-02",
      "citation": "INFL-INF08_02 (2017); Journal: inflammation_journal; Design: randomized controlled trial; Population: Adults with recovery concerns; Outcome: recovery; DOI: 10.1234/resveratrol-infl-inf08-02; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "INFL-INF08_03",
      "year": 2018,
      "design": "randomized controlled trial",
      "journal": "inflammation_journal",
      "outcome": "recovery",
      "population": "Adults with recovery concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/resveratrol-infl-inf08-03",
      "url": "https://doi.org/10.1234/resveratrol-infl-inf08-03",
      "citation": "INFL-INF08_03 (2018); Journal: inflammation_journal; Design: randomized controlled trial; Population: Adults with recovery concerns; Outcome: recovery; DOI: 10.1234/resveratrol-infl-inf08-03; Adverse Events: None reported."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/resveratrol-infl-inf08-01",
      "study_ids": [
        "INFL-INF08_01"
      ],
      "primary_study_id": "INFL-INF08_01",
      "url": "https://doi.org/10.1234/resveratrol-infl-inf08-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/resveratrol-infl-inf08-02",
      "study_ids": [
        "INFL-INF08_02"
      ],
      "primary_study_id": "INFL-INF08_02",
      "url": "https://doi.org/10.1234/resveratrol-infl-inf08-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/resveratrol-infl-inf08-03",
      "study_ids": [
        "INFL-INF08_03"
      ],
      "primary_study_id": "INFL-INF08_03",
      "url": "https://doi.org/10.1234/resveratrol-infl-inf08-03"
    }
  ],
  "manifest_hash": "sha256:281c4481719167c2240dc6c591b9696a820fc6cdec60a88d3d379fb7edde272d"
}
